Database : MEDLINE
Search on : neoplasms [Words]
References found : 1952742 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 195275 go to page                         

  1 / 1952742 MEDLINE  
              next record last record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 25789091
[Au] Autor:Kadiyala V; Lee LS
[Ad] Address:Vivek Kadiyala, Linda S Lee, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, MA 02115, United States.
[Ti] Title:Endosonography in the diagnosis and management of pancreatic cysts.
[So] Source:World J Gastrointest Endosc;7(3):213-23, 2015 Mar 16.
[Is] ISSN:1948-5190
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Rapid advances in radiologic technology and increased cross-sectional imaging have led to a sharp rise in incidental discoveries of pancreatic cystic lesions. These cystic lesions include non-neoplastic cysts with no risk of malignancy, neoplastic non-mucinous serous cystadenomas with little or no risk of malignancy, as well as neoplastic mucinous cysts and solid pseudopapillary neoplasms both with varying risk of malignancy. Accurate diagnosis is imperative as management is guided by symptoms and risk of malignancy. Endoscopic ultrasound (EUS) allows high resolution evaluation of cyst morphology and precise guidance for fine needle aspiration (FNA) of cyst fluid for cytological, chemical and molecular analysis. Initially, clinical evaluation and radiologic imaging, preferably with magnetic resonance imaging of the pancreas and magnetic resonance cholangiopancreatography, are performed. In asymptomatic patients where diagnosis is unclear and malignant risk is indeterminate, EUS-FNA should be used to confirm the presence or absence of high-risk features, differentiate mucinous from non-mucinous lesions, and diagnose malignancy. After analyzing the cyst fluid for viscosity, cyst fluid carcinoembryonic antigen, amylase, and cyst wall cytology should be obtained. DNA analysis may add useful information in diagnosing mucinous cysts when the previous studies are indeterminate. New molecular biomarkers are being investigated to improve diagnostic capabilities and management decisions in these challenging cystic lesions. Current guidelines recommend surgical pancreatic resection as the standard of care for symptomatic cysts and those with high-risk features associated with malignancy. EUS-guided cyst ablation is a promising minimally invasive, relatively low-risk alternative to both surgery and surveillance.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1503
[Cu] Class update date: 150321
[Lr] Last revision date:150321
[Da] Date of entry for processing:150319
[St] Status:PubMed-not-MEDLINE
[do] DOI:10.4253/wjge.v7.i3.213

  2 / 1952742 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 25789185
[Au] Autor:Chamseddine AN; Etancelin P; Penther D; Parmentier F; Kuadjovi C; Camus V; Contentin N; Lenain P; Bastard C; Tilly H; Jardin F
[Ad] Address:Department of Clinical Hematology, Henri Becquerel Cancer Center, 1 rue d'Amiens, 76038 Rouen, France ; Blood and Marrow Transplant Unit, Henri Becquerel Cancer Center, 1 rue d'Amiens, 76038 Rouen, France....
[Ti] Title:Transformation of an Unclassified Myeloproliferative Neoplasm with a Rare BCR-JAK2 Fusion Transcript Resulting from the Translocation (9;22)(p24;q11).
[So] Source:Case Rep Hematol;2015:252537, 2015.
[Is] ISSN:2090-6560
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BCR-ABL1 negative myeloproliferative neoplasms (MPNs) are known to contain alterations of the tyrosine kinase JAK2 (located on 9p24) that result in constitutive activation of the encoded protein. JAK2 fusions are reported in acute and chronic leukemias of myeloid and lymphoid phenotypes. Here, we report an unclassified case of MPN (MPN-U) showing a t(9;22)(p24;q11), which generates a BCR-JAK2 fusion gene by fusing the BCR at intron 13 to JAK2 at intron 17 on the derivative chromosome 22. Most reported JAK2 fusions cases reveal an aggressive clinical course and long-term remissions have only been achieved after allogeneic stem cell transplantation (ASCT). To the best of our knowledge, this is the thirteenth case reported worldwide to describe a BCR-JAK2 fusion transcript in MPN-U. The present report revealed a sustained complete clinical, hematologic, and cytogenetic remission 35 months after diagnosis and ~24 months after ASCT. Regarding BCR-ABL1 negative MPN patients this case report provides strong support for a role of JAK2 activation in the oncogenesis and suggests a possible diagnostic and therapeutic target that should be investigated.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1503
[Cu] Class update date: 150321
[Lr] Last revision date:150321
[Da] Date of entry for processing:150319
[St] Status:PubMed-not-MEDLINE
[do] DOI:10.1155/2015/252537

  3 / 1952742 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25557134
[Au] Autor:Mertens AC; Yong J; Dietz AC; Kreiter E; Yasui Y; Bleyer A; Armstrong GT; Robison LL; Wasilewski-Masker K
[Ad] Address:Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia.
[Ti] Title:Conditional survival in pediatric malignancies: Analysis of data from the Childhood Cancer Survivor Study and the Surveillance, Epidemiology, and End Results Program.
[So] Source:Cancer;121(7):1108-17, 2015 Apr 1.
[Is] ISSN:1097-0142
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Long-term survivors of pediatric cancer are at risk of life-threatening late effects of their cancer. Previous studies have shown excesses in long-term mortality within high-risk groups defined by demographic and treatment characteristics. METHODS: To investigate conditional survival in a pediatric cancer population, the authors performed an analysis of conditional survival in the original Childhood Cancer Survivor Study (CCSS) cohort and the Surveillance, Epidemiology, and End Results (SEER) database registry. The overall probability of death for patients at 5 years and 10 years after they survived 5, 10, 15, and 20 years since cancer diagnosis and cause-specific death in 10 years for 5-year survivors were estimated using the cumulative incidence method. RESULTS: Among patients in the CCSS and SEER cohorts who were alive 5 years after their cancer diagnosis, within each diagnosis group at least 92% were alive in the subsequent 5 years, except for patients with leukemia, of whom only 88% of 5-year survivors remained alive in the subsequent 5 years. The probability of all-cause mortality in the next 10 years among patients who survived at least 5 years after diagnosis was 8.8% in CCSS and 10.6% in SEER, approximately 75% of which was due to neoplasms as the cause of death. CONCLUSIONS: The risk of death among survivors of pediatric cancer in 10 years can vary between diagnosis groups by at most 12%, even up to 20 years after diagnosis. This information is clinically significant when counseling patients regarding their conditional survival, particularly when survivors are seen in long-term follow-up. Cancer 2015;121:1108-1117. © 2014 American Cancer Society.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1503
[Cu] Class update date: 150321
[Lr] Last revision date:150321
[Js] Journal subset:AIM; IM
[St] Status:In-Data-Review
[do] DOI:10.1002/cncr.29170

  4 / 1952742 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text

[PMID]: 25785131
[Au] Autor:Al-Daghri NM; Al-Attas O; Yakout S; Aljohani N; Al-Fawaz H; Alokail MS
[Ad] Address:Department of Biochemistry, Prince Mutaib Chair for Biomarkers of Osteoporosis, College of Science, King Saud University Riyadh 11451, Saudi Arabia ; Biomarkers Research Program, Department of Biochemistry, College of Science, King Saud University Riyadh 11451, Saudi Arabia....
[Ti] Title:Dietary products consumption in relation to serum 25-hydroxyvitamin D and selenium level in Saudi children and adults.
[So] Source:Int J Clin Exp Med;8(1):1305-14, 2015.
[Is] ISSN:1940-5901
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Vitamin D deficiency is a global health threat that has been associated with several chronic diseases. Selenium is an essential trace element because of role in major metabolic processes, immune function, thyroid hormone metabolism, male infertility, neoplasms and cardiovascular disease. We aimed to investigate for the first time in the Saudi population the association between vitamin D and selenium status with various dietary products consumption. A total of 259 children and 95 adults were included in this cross-sectional study. We estimated the consumption frequencies of various dietary food products using a qualitative food frequency questionnaire (FFQ) and also measured serum levels of 25-hydroxyvitamin D and selenium. Associations between variables of interest were assessed. Vitamin D deficiency and insufficiency were observed in 80% of the boys, 90% of the girls, 64% of men and 50% of women. Modest associations were found between mean serum 25 (OH) D concentration and consumption frequencies of fresh milk in children (r=0.11; P<0.05), more specifically in girls (r=0.12; P<0.05), and to the overall consumption of dairy products in women (r=0.12; P<0.05). Vitamin D status was also inversely associated with selenium in adults (r=-0.43; P<0.05). There was a significant correlation between delta changes of serum selenium, triglycerides and HDL levels (P-values <0.05). Vitamin D and selenium levels are modestly associated with dietary products consumption. Changes in selenium levels were associated with increased serum triglyceride levels, indicating a potential biomarker for cardiovascular risk and dyslipidemia. The widespread vitamin D deficiency observed in the present study highlight the need for adequate fortification of dairy products.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1503
[Cu] Class update date: 150321
[Lr] Last revision date:150321
[Da] Date of entry for processing:150318
[St] Status:PubMed-not-MEDLINE

  5 / 1952742 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 25785220
[Au] Autor:Battal M; Bostanci O; Basak T; Kartal K; Ekiz F
[Ad] Address:General Surgery Department, Sisli Etfal Research Hospital, Istanbul, Turkey....
[Ti] Title:Pure squamous cell carcinoma of the duodenum.
[So] Source:Case Rep Surg;2015:714640, 2015.
[Is] ISSN:2090-6900
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Primary carcinomas of the small intestine are extremely rare neoplasms. Most of these are adenocarcinomas. Primary squamous cell carcinoma (SCC) of small intestine is exceptionally rare with only occasional case reports in the literature. We report here a surgically treated patient with squamous cell carcinoma arising from duodenal diverticula in the third part of the duodenum.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1503
[Cu] Class update date: 150321
[Lr] Last revision date:150321
[Da] Date of entry for processing:150318
[St] Status:PubMed-not-MEDLINE
[do] DOI:10.1155/2015/714640

  6 / 1952742 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 24667222
[Au] Autor:Su L; Wernberg J
[Ad] Address:Surgical Resident, Department of General Surgery, Marshfield Clinic, Marshfield, Wisconsin, USA su.lowell@marshfieldclinic.org.
[Ti] Title:Synchronous distal pancreatic metastatic lesion arising from colonic adenocarcinoma: case report and literature review.
[So] Source:Clin Med Res;12(3-4):166-70, 2014 Dec.
[Is] ISSN:1554-6179
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Solitary metastatic pancreatic lesions comprise 0.5% to 3% of all pancreas neoplasms, most commonly arising from primary tumors of the kidney, lung, or colon. Synchronous metastatic pancreatic lesions are exceptionally rare. Only 25 cases of isolated colorectal pancreatic metastasis amenable to resection have been reported, 11 of those in the distal pancreas. To our knowledge we report the first case of a primary colonic malignancy with a synchronous distal pancreatic metastatic lesion treated with resection.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1502
[Cu] Class update date: 150209
[Lr] Last revision date:150209
[Js] Journal subset:IM
[St] Status:In-Process
[do] DOI:10.3121/cmr.2013.1195

  7 / 1952742 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25401981
[Au] Autor:Agalliu I; San Luciano M; Mirelman A; Giladi N; Waro B; Aasly J; Inzelberg R; Hassin-Baer S; Friedman E; Ruiz-Martinez J; Marti-Masso JF; Orr-Urtreger A; Bressman S; Saunders-Pullman R
[Ad] Address:Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York....
[Ti] Title:Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.
[So] Source:JAMA Neurol;72(1):58-65, 2015 Jan.
[Is] ISSN:2168-6157
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:IMPORTANCE: Patients with Parkinson disease (PD) who harbor LRRK2 G2019S mutations may have increased risks of nonskin cancers. However, the results have been inconsistent across studies. OBJECTIVES: To analyze pooled data from 5 centers to further examine the association between LRRK2 G2019S mutation and cancer among patients with PD and to explore factors that could explain discrepancies. DESIGN, SETTING, AND PARTICIPANTS: Clinical, demographic, and genotyping data as well as cancer outcomes were pooled from 1549 patients with PD recruited across 5 movement disorders clinics located in Europe, Israel, and the United States. Associations between LRRK2 G2019S mutation and the outcomes were examined using mixed-effects logistic regression models to estimate odds ratios (ORs) and 95% CIs. Models were adjusted for age and ethnicity (Ashkenazi Jewish vs others) as fixed effects and study center as a random effect. MAIN OUTCOMES AND MEASURES: All cancers combined, nonskin cancers, smoking-related cancers, hormone-related cancers, and other types of cancer. RESULTS: The overall prevalence of the LRRK2 G2019S mutation was 11.4% among all patients with PD. Mutation carriers were younger at PD diagnosis and more likely to be women (53.1%) and of Ashkenazi Jewish descent (76.8%) in comparison with individuals who were not mutation carriers. The LRRK2 G2019S mutation carriers had statistically significant increased risks for nonskin cancers (OR, 1.62; 95% CI, 1.04-2.52), hormone-related cancers (OR, 1.87; 95% CI, 1.07-3.26) and breast cancer (OR, 2.34; 95% CI, 1.05-5.22) in comparison with noncarriers. There were no associations with other cancers. There were no major statistically significant differences in the results when the data were stratified by Ashkenazi Jewish ethnicity; however, there was some evidence of heterogeneity across centers. CONCLUSIONS AND RELEVANCE: This multinational study from 5 centers demonstrates that LRRK2 G2019S mutation carriers have an overall increased risk of cancer, especially for hormone-related cancer and breast cancer in women. Larger prospective cohorts or family-based studies investigating associations between LRRK2 mutations and cancer among patients with PD are warranted to better understand the underlying genetic susceptibility between PD and hormone-related cancers.
[Mh] MeSH terms primary: Genetic Predisposition to Disease/genetics
Mutation/genetics
Neoplasms/genetics
Parkinson Disease/genetics
Protein-Serine-Threonine Kinases/genetics
[Mh] MeSH terms secundary: Aged
Aged, 80 and over
Europe
Female
Genetic Association Studies
Genotype
Glycine/genetics
Humans
Israel
Male
Middle Aged
Neoplasms/classification
Neoplasms/complications
Odds Ratio
Parkinson Disease/complications
Sensitivity and Specificity
Sex Factors
United States
[Pt] Publication type:JOURNAL ARTICLE; MULTICENTER STUDY; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:EC 2.7.11.1 (LRRK2 protein, human); EC 2.7.11.1 (Protein-Serine-Threonine Kinases); TE7660XO1C (Glycine)
[Em] Entry month:1503
[Cu] Class update date: 150321
[Lr] Last revision date:150321
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:150113
[St] Status:MEDLINE
[do] DOI:10.1001/jamaneurol.2014.1973

  8 / 1952742 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25381395
[Au] Autor:Moossdorff M; van Roozendaal LM; Strobbe LJ; Aebi S; Cameron DA; Dixon JM; Giuliano AE; Haffty BG; Hickey BE; Hudis CA; Klimberg VS; Koczwara B; Kühn T; Lippman ME; Lucci A; Piccart M; Smith BD; Tjan-Heijnen VC; van de Velde CJ; Van Zee KJ; Vermorken JB; Viale G; Voogd AC; Wapnir IL; White JR; Smidt ML
[Ad] Address:Department of Surgery and GROW School for Oncology and Developmental Biology (MM, MLS), Department of Surgery and Radiology (LMvR), Department of Medical Oncology, GROW School for Oncology and Developmental Biology (VCGTH), and Department of Epidemiology and GROW School for Oncology and Developmenta...
[Ti] Title:Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research.
[So] Source:J Natl Cancer Inst;106(12), 2014 Dec.
[Is] ISSN:1460-2105
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: In breast cancer studies, many different endpoints are used. Definitions are often not provided or vary between studies. For instance, "local recurrence" may include different components in similar studies. This limits transparency and comparability of results. This project aimed to reach consensus on the definitions of local event, second primary breast cancer, regional and distant event for breast cancer studies. METHODS: The RAND-UCLA Appropriateness method (modified Delphi method) was used. A Consensus Group of international breast cancer experts was formed, including representatives of all involved clinical disciplines. Consensus was reached in two rounds of online questionnaires and one meeting. RESULTS: Twenty-four international breast cancer experts participated. Consensus was reached on 134 items in four categories. Local event is defined as any epithelial breast cancer or ductal carcinoma in situ (DCIS) in the ipsilateral breast, or skin and subcutaneous tissue on the ipsilateral thoracic wall. Second primary breast cancer is defined as epithelial breast cancer in the contralateral breast. Regional events are breast cancer in ipsilateral lymph nodes. A distant event is breast cancer in any other location. Therefore, this includes metastasis in contralateral lymph nodes and breast cancer involving the sternal bone. If feasible, tissue sampling of a first, solitary, lesion suspected for metastasis is highly recommended. CONCLUSION: This project resulted in consensus-based event definitions for classification of recurrence in breast cancer research. Future breast cancer research projects should adopt these definitions to increase transparency. This should facilitate comparison of results and conducting reviews as well as meta-analysis.
[Mh] MeSH terms primary: Breast Neoplasms/diagnosis
Neoplasm Recurrence, Local/diagnosis
Neoplasms, Second Primary/diagnosis
[Mh] MeSH terms secundary: Breast Neoplasms/pathology
Carcinoma, Intraductal, Noninfiltrating/diagnosis
Delphi Technique
Female
Humans
International Cooperation
Lymphatic Metastasis
Neoplasm Recurrence, Local/pathology
Neoplasms, Second Primary/pathology
Questionnaires
Skin Neoplasms/secondary
Thoracic Wall/pathology
[Pt] Publication type:CONSENSUS DEVELOPMENT CONFERENCE; JOURNAL ARTICLE
[Em] Entry month:1501
[Cu] Class update date: 150321
[Lr] Last revision date:150321
[Js] Journal subset:IM
[Da] Date of entry for processing:141108
[St] Status:MEDLINE

  9 / 1952742 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 24986120
[Au] Autor:Curley SA; Palalon F; Lu X; Koshkina NV
[Ad] Address:Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Mechanical Engineering and Materials Science, Rice University, Houston, Texas.
[Ti] Title:Noninvasive radiofrequency treatment effect on mitochondria in pancreatic cancer cells.
[So] Source:Cancer;120(21):3418-25, 2014 Nov 1.
[Is] ISSN:1097-0142
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: The development of novel therapeutic approaches for cancer therapy is important, especially for tumors that have poor response or develop resistance to standard chemotherapy and radiation. We discovered that noninvasive radiofrequency (RF) fields can affect cancer cells but not normal cells, inhibit progression of tumors in mice, and enhance the anticancer effects of chemotherapy. However, it remains unclear what physiological and molecular mechanisms this treatment induces inside cells. Here, we studied the effect of RF treatment on mitochondria in human pancreatic cancer cells. METHODS: The morphology of mitochondria in cells was studied via electron microscopy. The alteration of mitochondrial membrane potential (Δψ) was accessed using a Mitotracker probe. The respiratory activity of mitochondria was evaluated by analyzing changes in oxygen consumption rates determined with a Mito Stress Test Kit. The production of intracellular reactive oxygen species was performed using flow cytometry. The colocalization of mitochondria and autophagosome markers in cells was performed using fluorescence immunostaining and confocal microscopy analysis. RESULTS: RF fields treatment changed the morphology of mitochondria in cancer cells, altered polarization of the mitochondrial membrane, substantially impaired mitochondrial respiration, and increased reactive oxygen species production, indicating RF-induced stress on the mitochondria. We also observed frequent colocalization of the autophagosome marker LC3B with the mitochondrial marker Tom20 inside cancer cells after RF exposure, indicating the presence of mitochondria in the autophagosomes. This suggests that RF-induced stress can damage mitochondria and induce elimination of damaged organelles via autophagy. CONCLUSION: RF treatment impaired the function of mitochondria in cancer cells. Therefore, mitochondria can represent one of the targets of the RF treatment.
[Mh] MeSH terms primary: Membrane Potential, Mitochondrial/radiation effects
Mitochondria/radiation effects
Pancreatic Neoplasms/radiotherapy
Radio Waves/therapeutic use
[Mh] MeSH terms secundary: Animals
Apoptosis/radiation effects
Autophagy/radiation effects
Cell Line, Tumor
Humans
Mice
Microscopy, Electron, Transmission
Mitochondria/ultrastructure
Pancreatic Neoplasms/pathology
Reactive Oxygen Species/metabolism
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Reactive Oxygen Species)
[Em] Entry month:1503
[Cu] Class update date: 150321
[Lr] Last revision date:150321
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:141021
[St] Status:MEDLINE
[do] DOI:10.1002/cncr.28895

  10 / 1952742 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 25139676
[Au] Autor:Liss MA; Stroup SP; Qin Z; Hoh CK; Hall DJ; Vera DR; Kane CJ
[Ad] Address:Department of Urology, UC San Diego Health System, San Diego, CA; UCSD Moores Cancer Center, La Jolla, CA....
[Ti] Title:Robotic-assisted fluorescence sentinel lymph node mapping using multimodal image guidance in an animal model.
[So] Source:Urology;84(4):982.e9-14, 2014 Oct.
[Is] ISSN:1527-9995
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:OBJECTIVE: To investigate positron emission tomography/computed tomography (PET/CT) preoperative imaging and intraoperative detection of a fluorescent-labeled receptor-targeted radiopharmaceutical in a prostate cancer animal model. MATERIALS AND METHODS: Three male beagle dogs underwent an intraprostatic injection of fluorescent-tagged tilmanocept, radiolabeled with both gallium Ga-68 and technetium Tc-99m. One hour after injection, a pelvic PET/CT scan was performed for preoperative sentinel lymph node (SLN) mapping. The definition of SLN was a standardized uptake value that exceeded 5% of the lymph node with the highest standardized uptake value. Thirty-six hours later, we performed robotic-assisted SLN dissection using a fluorescence-capable camera system. Fluorescent lymph nodes were clipped, the abdomen was opened, and the pelvic and retroperitoneal nodes were excised. All excised nodal packets were assayed by in vitro nuclear counting and reported as the percentage of injected dose. RESULTS: Preoperative PET/CT imaging identified a median of 3 SLNs per animal. All SLNs (100%) identified by the PET/CT were fluorescent during robotic-assisted lymph node dissection. Of all fluorescent nodes visualized by the camera system, 9 of 12 nodes (75%) satisfied the 5% rule defined by the PET/CT scan. The 2 lymph nodes that did not qualify accumulated <0.002% of the injected dose. CONCLUSION: Fluorescent-labeled tilmanocept has optimal logistic properties to obtain preoperative PET/CT and subsequent real-time intraoperative confirmation during robotic-assisted SLN dissection.
[Mh] MeSH terms primary: Dextrans/diagnostic use
Multimodal Imaging
Positron-Emission Tomography
Prostate/pathology
Prostatic Neoplasms/pathology
Radiopharmaceuticals/diagnostic use
Robotic Surgical Procedures
Sentinel Lymph Node Biopsy/methods
Technetium Tc 99m Pentetate/analogs & derivatives
Tomography, X-Ray Computed
[Mh] MeSH terms secundary: Animals
Disease Models, Animal
Dogs
Image-Guided Biopsy
Male
Preoperative Care
Technetium Tc 99m Pentetate/diagnostic use
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Radiopharmaceuticals); 0 (gallium-diethylenetriaminepentaacetic acid-mannosyl-dextran); K3R6ZDH4DU (Dextrans); VW78417PU1 (Technetium Tc 99m Pentetate)
[Em] Entry month:1502
[Cu] Class update date: 150321
[Lr] Last revision date:150321
[Js] Journal subset:IM
[Da] Date of entry for processing:140927
[St] Status:MEDLINE


page 1 of 195275 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information